DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2026)

DiaMedica Therapeutics has reported Cash from Operations for 9 years, with the latest figure at 9100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 27.29% year-over-year to 9100000.0; the trailing twelve-month figure through Mar 2026 stood at 31013000.0 (down 37.4% YoY), and the FY2025 full-year result was 29062000.0, down 31.65% from the prior year.
• Cash from Operations for Q1 2026 stood at 9100000.0, down from 7762000.0 in the prior quarter.
• The five-year high for Cash from Operations was 2361000.0 in Q3 2022, with the low at 9100000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 5322176.47 across 5 years, with a median of 5030000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations climbed 22.49% — and 2023, when it sank 103.18%.
• DiaMedica Therapeutics' Cash from Operations stood at 2766000.0 in 2022, then slumped by 37.82% to 3812000.0 in 2023, then slumped by 68.78% to 6434000.0 in 2024, then fell by 20.64% to 7762000.0 in 2025, then fell by 17.24% to 9100000.0 in 2026.
• The last three Cash from Operations figures came in at 9100000.0 (Q1 2026), 7762000.0 (Q4 2025), and 6600000.0 (Q3 2025), per Business Quant data.